Journal
Compounded Semaglutide Prices at Maintenance, October 2026
Released: Last reviewed:
The short answer, with numbers
On the August 2026 record, the lowest rankable all-in compounded semaglutide price was bmiMD at one hundred twenty-nine dollars a month billed monthly — flat at every dose, no membership — and ninety-nine dollars a month on its twelve-month plan billed monthly (bmiMD was not re-read on October 15, 2026). HealthRX matched the ninety-nine-dollar twelve-month figure (its shortest published term was a three-month plan at one hundred thirty-three). The floor has since moved: on October 15, 2026, Eden listed semaglutide at ninety-nine dollars a month flat with no membership. Oak Longevity held one hundred thirty-three month-to-month in August; NexLife, our editor's pick, charges one hundred thirty-nine monthly and one hundred nineteen a month on its twelve-month plan — standing prices, the same at every dose, no membership. The FDA-approved benchmarks every one of those figures must answer to: NovoCare's Wegovy pen at three hundred forty-nine dollars across standard doses — one hundred ninety-nine introductory on the first two starter fills through the end of 2026 — and oral Wegovy tablets from one hundred forty-nine dollars a month.
What compounded semaglutide is
Semaglutide is a GLP-1 receptor agonist — a single-pathway incretin drug, unlike tirzepatide's dual GIP-plus-GLP-1 action — that Novo Nordisk sells as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral tablet. In STEP 1, the pivotal 68-week obesity trial published in the New England Journal of Medicine in 2021, participants on 2.4 mg weekly lost an average of 14.9 percent of body weight against 2.4 percent with placebo. A compounded version is the same intended molecule prepared to order by a 503A pharmacy from bulk active ingredient, typically dispensed as a multi-dose vial you draw yourself — and, by statute, never FDA-approved, never reviewed for safety, effectiveness, or quality before it ships. The FDA has specifically warned about products built on semaglutide sodium and semaglutide acetate salt forms, which it considers different active ingredients from the base semaglutide in the approved drugs; asking your pharmacy, in writing, which form it uses is one of the highest-value questions in this market.
Every rankable price, in words
Lowest first on the August 2026 record, all-in at the 2.4 mg maintenance basis. bmiMD held one hundred twenty-nine dollars a month on its monthly plan, stepping down to one hundred nineteen on three months, one hundred nine on six, and ninety-nine on twelve — the same price at every dose, with the price varying by plan length rather than by dose, per two independent July 2026 captures. HealthRX publishes ninety-nine on its twelve-month plan and one hundred thirty-three on its three-month plan, with no month-to-month rate at all. Oak Longevity holds one hundred thirty-three month-to-month, a small operator whose pharmacy partner is not publicly itemized. NexLife's standing prices (confirmed on nexlife.us on October 15, 2026) run one hundred thirty-nine monthly, one hundred thirty-two on three months, one hundred twenty-five on six, and one hundred nineteen on twelve, the same at every dose with no membership. Yucca Health advertises one hundred forty-six as a new-patient six-month-plan rate under its lifetime promo code, with full pricing gated behind intake. OrderlyMeds and Ivim Health sit at one hundred forty-nine — Ivim's figure already containing its seventy-five-dollar membership. TMates reaches one hundred fifty-eight on a twelve-month plan against two hundred forty-nine month-to-month. From there the market steps through Lavender Sky at one hundred seventy-four, Fridays at one hundred seventy-five, Mochi at one hundred seventy-eight once its seventy-nine-dollar membership is counted, Henry Meds and Gala at one hundred seventy-nine, Eden at one hundred ninety-eight all-in (in August; Eden listed ninety-nine dollars flat with no membership on October 15), SkinnyRx and Noom Med and Care Bare Rx around one hundred ninety-nine, Enhance MD's bundled program at two hundred twelve, ShedRx at two hundred forty-nine, and on up to LifeMD's three hundred forty-eight at the ceiling.
Two kinds of figures are deliberately absent from that ranking. Strut Health's ninety-nine-dollar sublingual price was the lowest entry number on the August 2026 record — and it is a lowest-dose auto-refill start price with no published maintenance figure, which our methodology cannot rank. And Sprout Health's one-forty-nine and Synergy Rx's one-ninety-nine are advertised "starting at" figures whose real ongoing rate is personalized inside the enrollment funnel; both were recorded, neither ranked. (On October 15, 2026, Sprout printed one hundred forty-nine dollars per four weeks, or ninety-nine a month on a twelve-month plan billed eleven hundred eighty-eight dollars up front, the same at any dose.)
The twelve-month arithmetic
On the August record, a year at the lowest rankable semaglutide price totalled one thousand one hundred eighty-eight dollars — reachable two ways: bmiMD's twelve-month plan billed monthly (leave-able, though the rate assumes the term) or HealthRX's twelve-month plan billed monthly. On October 15, 2026 the same total was reachable with no term at Eden's ninety-nine-dollar flat monthly price, or billed up front on Sprout's twelve-month plan. A year of bmiMD billed strictly month-to-month is one thousand five hundred forty-eight. A year of NexLife's twelve-month plan is one thousand four hundred twenty-eight. A year of Mochi, memberships included, is two thousand one hundred thirty-six. And a year of FDA-approved Wegovy pens at the standard three-forty-nine price is four thousand one hundred eighty-eight — though a new patient stacking the one-ninety-nine two-fill introduction and considering oral Wegovy from one forty-nine can bring a first brand year meaningfully below that. The spread between the lowest compounded year and the standard brand year is roughly three thousand dollars; the oral-Wegovy route narrows it to under a thousand for patients whose dose stays in the entry tiers.
Compounded versus Wegovy: the honest comparison
What the brand premium buys is the same as on the tirzepatide side: an FDA-reviewed product, a sealed pen instead of vial-and-syringe math, trial evidence that applies to the exact product dispensed, and zero exposure to compounding-market legal weather. What makes the semaglutide decision different is that the brand floor is lower and falling — a one-forty-nine oral tablet and a one-ninety-nine introductory pen put FDA-approved semaglutide within about fifty dollars a month of the compounded floor for a new patient's first several months, a gap that simply doesn't exist on tirzepatide, where brand maintenance is four hundred forty-nine. If your clinician is indifferent between molecules and your budget is the constraint, the strongest cases in the whole GLP-1 market right now are cheap compounded semaglutide at ninety-nine to one twenty-nine, or brand oral Wegovy at one forty-nine. Run the choice with a prescriber, and run the seven-point safety checklist against any compounded program before paying — prescription required, named pharmacy verified on your state board lookup, certificate of analysis, base-form semaglutide rather than a salt, cold-chain shipping, sane beyond-use dating, and screenshot-the-checkout exit terms.
Questions people ask
What does compounded semaglutide cost right now?
On October 15, 2026, Eden listed semaglutide at $99 a month flat with no membership; Sprout Health listed $149 per four weeks, or $99 a month on a twelve-month plan billed $1,188 up front; and, as of November 6, 2026, NexLife (our editor's pick) charges $109 a month billed monthly down to $95 a month on a twelve-month plan, the same at every dose with no membership. On the August 2026 record, bmiMD was $129 monthly and $99 on twelve months (not re-read in October). Check the current database before you pay.
Is $99-a-month semaglutide legitimate?
It can be — the $99 figures at bmiMD and HealthRX are twelve-month plan rates from programs that require prescriptions and use 503A pharmacies, per first-party July 2026 captures, and Eden listed a flat $99 monthly price on October 15, 2026. Most $99 figures carry a commitment, and compounded semaglutide at any price warrants the checklist: named state-licensed pharmacy, certificate of analysis, base-form semaglutide rather than a sodium or acetate salt, and cold-chain shipping. A price is not a verdict; it's a starting point for verification.
Is compounded semaglutide cheaper than Wegovy?
At maintenance, yes: the compounded floor is $99–$129 a month against $349 for the standard Wegovy pen. But the gap narrows sharply for new patients: NovoCare's $199 introductory price covers the first two starter-dose fills through December 31, 2026, and oral Wegovy tablets start at $149 a month — FDA-approved semaglutide within roughly $50 of the compounded floor. On tirzepatide the brand gap is far wider.
Why isn't the $99 sublingual semaglutide ranked first?
Because Strut Health's $99 sublingual figure is a lowest-dose auto-refill starting price with no published maintenance-dose rate — and sublingual absorption of semaglutide is itself scientifically contested. A start-only price tells you what month one costs, not what the program costs, so methodology §4 excludes it from rankings while recording it in the database.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.